Thu, December 19, 2024
[ Thu, Dec 19th 2024 ] - WSPA
Limitless Fit-3 Mobility Exercises
Wed, December 18, 2024
[ Wed, Dec 18th 2024 ] - fbcnews
Lovo on a quest to fulfil his dream
Tue, December 17, 2024
[ Tue, Dec 17th 2024 ] - AOL
Get paid to work out with these 9 apps
[ Tue, Dec 17th 2024 ] - MSN
Gym wins fitness title
Mon, December 16, 2024
[ Mon, Dec 16th 2024 ] - Science Daily
Teen Health News
[ Mon, Dec 16th 2024 ] - Uber
Health & Fitness App 2024 Market Map
Sun, December 15, 2024
[ Sun, Dec 15th 2024 ] - Los Angeles Times
The Power of Resiliency
[ Sun, Dec 15th 2024 ] - kathmandupost
Nepal's trail opportunities

Is Viking Therapeutics, Inc. (VKTX) the Best Weight Loss Stock to Buy Now According to Hedge Funds?


//health-fitness.news-articles.net/content/2024/ .. s-stock-to-buy-now-according-to-hedge-funds.html
Published in Health and Fitness on Tuesday, December 17th 2024 at 6:23 GMT by MSN   Print publication without navigation

  • We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against the other weight loss stocks.

The article from MSN discusses the potential of Viking Therapeutics Inc. (VKTX) as a promising investment in the weight loss sector, particularly highlighted by its recent developments and hedge fund interest. Viking Therapeutics has gained attention due to its drug VK2735, which has shown significant weight loss results in early clinical trials, positioning the company as a potential competitor to established players like Eli Lilly and Novo Nordisk. The article notes that hedge funds have been increasing their stakes in VKTX, with notable investors like Citadel Investment Group and Renaissance Technologies showing interest. This surge in hedge fund investment is attributed to the promising data from Viking's trials, suggesting that the company could be a lucrative option for investors looking at the weight loss market. However, the article also cautions that while the stock has potential, it remains speculative due to the inherent risks associated with biotech investments, including the need for further successful trials and regulatory approval.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/health/weightloss/is-viking-therapeutics-inc-vktx-the-best-weight-loss-stock-to-buy-now-according-to-hedge-funds/ar-AA1w0I1i ]

Publication Contributing Sources